nifekalant hydrochloride has been researched along with Arrhythmia in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (12.50) | 18.2507 |
| 2000's | 4 (50.00) | 29.6817 |
| 2010's | 2 (25.00) | 24.3611 |
| 2020's | 1 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, Q; Tao, L; Xiao, H | 1 |
| Chiba, K; Ishizaka, T; Maeda, Y; Mori, K; Yoshimatsu, Y | 1 |
| Chinushi, M; Furushima, H; Izumi, D; Sato, A | 1 |
| Hashimoto, K; Noda, Y | 1 |
| Hamano, K; Murakami, M; Nishida, M; Okada, H | 1 |
| Fujiki, A | 1 |
| Hashimoto, K; Nakamura, H; Nouchi, H; Shigenobu, K; Shimada, H; Sugiyama, A; Takahara, A; Takeda, K; Tamura, M; Tamura, T; Tanaka, H; Tanaka, T; Tsuruoka, N | 1 |
| Aye, NN; Hashimoto, K; Xue, Y; Yamada, C | 1 |
1 review(s) available for nifekalant hydrochloride and Arrhythmia
| Article | Year |
|---|---|
[Present status in and prospects for anti-arrhythmic drug therapy: How to use type III anti-arrhythmic agents].
Topics: Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Bepridil; Drug Therapy, Combination; Humans; Pyrimidinones; Sotalol | 2006 |
7 other study(ies) available for nifekalant hydrochloride and Arrhythmia
| Article | Year |
|---|---|
Long-term nifekalant use in a patient with dilated cardiomyopathy and recurrent ventricular tachycardia.
Topics: Adult; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Cardiomyopathy, Dilated; Humans; Male; Pyrimidinones; Tachycardia, Ventricular | 2022 |
Negative lusitropic property of nifekalant identified using ventricular pressure-volume loop analyses in anesthetized monkeys.
Topics: Anesthesia; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Cardiac Volume; Depression, Chemical; Diastole; Dose-Response Relationship, Drug; Electrocardiography; Heart Rate; Hemodynamics; Infusions, Intravenous; Macaca fascicularis; Male; Myocardial Contraction; Pyrimidinones; Ventricular Function, Left; Ventricular Pressure | 2019 |
Nifekalant enlarged the transmural activation-recovery interval difference as well as the peak-to-end interval on surface ECG in a patient with short-QT syndrome.
Topics: Action Potentials; Adolescent; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Cardiac Pacing, Artificial; Electrocardiography; Electrophysiologic Techniques, Cardiac; Fatal Outcome; Female; Heart Conduction System; Heart Defects, Congenital; Heart Rate; Humans; Predictive Value of Tests; Pyrimidinones; Time Factors; Treatment Outcome | 2012 |
Development of a halothane-adrenaline arrhythmia model using in vivo Guinea pigs.
Topics: Adrenergic alpha-Agonists; Anesthetics, Inhalation; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Diltiazem; Electrocardiography; Epinephrine; Guinea Pigs; Halothane; Long QT Syndrome; Male; Pyrimidinones; Vagotomy | 2004 |
[Treatment for perioperative arrhythmias with nifekalant hydrochloride].
Topics: Adult; Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Flutter; Cardiac Surgical Procedures; Female; Humans; Male; Middle Aged; Postoperative Complications; Pyrimidinones; Tachycardia, Ventricular; Ventricular Fibrillation | 2006 |
Analysis of arrhythmogenic profile in a canine model of chronic atrioventricular block by comparing in vitro effects of the class III antiarrhythmic drug nifekalant on the ventricular action potential indices between normal heart and atrioventricular bloc
Topics: Action Potentials; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Dogs; Dose-Response Relationship, Drug; Heart Block; Heart Ventricles; Microelectrodes; Purkinje Fibers; Pyrimidinones | 2007 |
MS-551 and KCB-328, two class III drugs aggravated adrenaline-induced arrhythmias.
Topics: Adrenergic alpha-Agonists; Adrenergic beta-Antagonists; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Blood Pressure; Dogs; Electrocardiography; Epinephrine; Female; Heart Rate; Hemodynamics; In Vitro Techniques; Male; Phenethylamines; Propranolol; Pyrimidinones; Sulfonamides | 1998 |